Extended Data Fig. 2: T cell characteristics in tumor and blood.

(a) Stacked bar graph demonstrating patient-wise immune cell composition of ER+ IDC tumors (n = 29) (b)Stacked bar graph demonstrating patient-wise immune cell composition of ER+ ILC tumors (n = 24) (c) Pie chart depicting the median percent of T cell functional phenotype composition for CD4⁺ Tconv (left) and CD8⁺ T cells (right) in ER+ TIL (top panel) and ER+ PBL (bottom panel) (d) Profile of inhibitory receptors PD-1, TIGIT, LAG3, TIM3 and CTLA4 expression on CD8⁺ T cells in ER+ IDC PBL (n = 34 samples) and TIL (n = 25 samples) (left panel) and ER+ ILC PBL (n = 10 samples) and TIL (n = 10 samples) right panel. Dotted line along Y axis marks 10% of all cells. Two-sided paired Wilcoxon Rank Test was used for statistical analysis. (e) Profile of inhibitory receptors PD-1, TIGIT, LAG3, TIM3 and CTLA4 expression on CD4⁺ T cells in ER+ IDC PBL (n = 34 samples) and TIL (n = 25 samples) (left panel) and ER+ ILC PBL (n = 10 samples) and TIL (n = 10 samples) right panel. Dotted line along Y axis denoted 10% of all cells. Two-sided paired Wilcoxon Rank Test was used for statistical analysis.